Infinity Pharmaceuticals (INFI) Issues Earnings Results
Infinity Pharmaceuticals (NASDAQ:INFI) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03, Fidelity Earnings reports. The firm had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.05 million.
Shares of Infinity Pharmaceuticals stock traded down $0.02 during trading on Friday, reaching $1.89. The company had a trading volume of 186,287 shares, compared to its average volume of 231,660. The firm has a market cap of $81.89 million, a PE ratio of -2.28 and a beta of 2.17. Infinity Pharmaceuticals has a fifty-two week low of $1.00 and a fifty-two week high of $2.92.
Several large investors have recently made changes to their positions in INFI. Fosun International Ltd bought a new stake in shares of Infinity Pharmaceuticals during the 3rd quarter valued at about $879,000. Dimensional Fund Advisors LP grew its position in shares of Infinity Pharmaceuticals by 14.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,065,874 shares of the biotechnology company’s stock valued at $2,889,000 after buying an additional 133,504 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Infinity Pharmaceuticals by 35.7% during the 3rd quarter. Renaissance Technologies LLC now owns 736,700 shares of the biotechnology company’s stock valued at $1,996,000 after buying an additional 194,000 shares during the last quarter. EcoR1 Capital LLC grew its position in shares of Infinity Pharmaceuticals by 12.2% during the 3rd quarter. EcoR1 Capital LLC now owns 462,068 shares of the biotechnology company’s stock valued at $1,252,000 after buying an additional 50,068 shares during the last quarter. Finally, Opaleye Management Inc. bought a new stake in shares of Infinity Pharmaceuticals during the 3rd quarter valued at about $745,000. 54.12% of the stock is owned by institutional investors and hedge funds.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Featured Story: Short Selling
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.